An article published online first and in a next issue of the Lancet reports, new research based on a meta-analysis of thirteen Statin trials have shown that the use of Statins increases the risk of developing diabetes type 2 of 9 percent. However, is the absolute risk low, especially compared to the beneficial effects of Statins coronary accident reduction. The article is the work of Professor Naveed Satar and Dr. David Preiss, heart cardiovascular research center of Glasgow, the University of Glasgow, UK and his colleagues.
Studies of statin therapy on the risk of developing diabetes in patients that statins have had contradictory results. Remove this doubt, have the authors to determine whether a relationship between statin use and development of diabetes there is meta-analysis of published and unpublished.
The thirteen period 1994-2009 studies were included. Every attempt had more than 1000 patients with identical follow-up in statins and not Statin groups and more than a year. The suffering of patients with organ transplants, or needed for hemodialysis, were excluded. Thirteen Statin studies identified a total of 91 140 participants included. Of these employees developed 4 278 diabetes on an average of four years. Total 2 226 Statins were assigned, and 2 052 control therapy were assigned. Statin therapy has been assigned a percentage of 9 increased risk of developing diabetes. There was the consistency of risk through the trials. Further analysis showed that the risk of developing diabetes with Statins in studies with former participants was higher. Appear on the other hand, body-mass index and changes in cholesterol LDL (bad) do not affect the risk with Statins, diabetes to develop. Treatment of 255 with Statins for four years led to a further case of diabetes.
Researchers emphasize that the results not, that risks statin therapy to increase of diabetes through a direct molecular mechanisms. However, it should examine the possibility. However the increased risk could be linked somehow, to statin therapy. A slight improvement of survival on Statins compensated for the increased risk of developing diabetes. Although the authors are questionable, they say that the increased risk of diabetes in these Statins may be conclusive.
The treatment of 255 with Statins for four years in another case of diabetes would lead in perspective. However, 255 same patients 1 mmol/L concentrations could (bad) cholesterol the Statins would cause reduction of LDL, the experience of the five large expect less coronary events such as the death of coronary heart disease or non-fatal heart attack.
The authors recommend that the seniors, the treatment with Statins for the development of diabetes could be monitoring beneficial, as they seem particularly vulnerable. They explain: "we recommend that the development of diabetes is specified as a secondary endpoint in the future studies show large Statin and suggest that you, as far as possible, monitoring in the long term also cross diabetes should be included in the existing studies".
Finally, they write: "in view of the overwhelming advantage of which is Statins to reduce heart-vascular events, low absolute risk of developing diabetes heart cardiovascular benefits in the short and medium term term people predominate, for the statin therapy recommended." We suggest that clinical practice for statin, not need therapy in patients with moderate or high cardiovascular risk or -cardiovascular diseases, which modify existing. However, should the risk of diabetes may be increased, if statin therapy for patients in low cardiovascular risk or patient groups that heart-circulation advantage has not been proven. »
In a related, Dr. Christopher note P Cannon, heart-circulation area, Brigham and women's Hospital and Harvard Medical School, Boston; and Office for the study of the TIMI, Boston, MA, United States, comments on the study. It examines how the authors this study provides, that the death or heart attack could be avoided 5 • 4, over four years. Almost the same number of strokes or coronary Revascularization could also avoid procedure. Dr. Cannon noted: "thus the advantage [taking statins] total vascular accident for the risk of diabetes prevention is a report of 9: 1 for the heart-vascular performance." The advantage seems so strongly outweigh the risks. »
In conclusion, he said: "yet newly identified risk guarantees of the monitoring, and as such in the regular monitoring of liver it seems reasonable tests and creatine kinase, to glucose in the list of tests to the older patients add statins." "Thus, while new risks of Statins has been identified, the risk appears far surpassed by the advantage of this class, to save the life of drugs and small".